Home » Newsletters » BioWorld Science

BioWorld Science

April 19, 2016

View Archived Issues

Discovery of a potent and selective BCR-ABL inhibitor for chronic myeloid leukemia

Scientists steer ligand bias between beta-arrestin 2 and G protein pathway for biased CXCR3 agonists

Lead Discovery Center and Merck KGaA report proteasome inhibitors

Shanghai Haiyan Pharmaceutical Technology and Yangtze River Pharmaceutical disclose EGFR inhibitors

Domain Therapeutics patents metabotropic glutamate receptor modulators

Hutchison MediPharma announces PI3K inhibitors

FDA grants breakthrough therapy designation to Keytruda in classical Hodgkin's lymphoma

Merck & Co. patent describes IRAK-4 inhibitors

Update on the type 2 diabetes drug candidate TT-401

FDA approves Photrexa Viscous, Photrexa and KXL System to treat progressive keratoconus

Phase II GAMES results reported for RP-1127 for prevention of edema after ischemic stroke

NiCox submits NDA for AC-170 to treat ocular itching associated with allergic conjunctivitis

ImmunoBiochem and CCAB partner to develop antibody-drug conjugates for breast cancer

Milestone achieved in DR5 antibody collaboration between iDD biotech and Genmab

NDI-010976 shows dose-dependent inhibition of de novo lipogenesis in the liver in phase Ib trial

Selvita submits IND for SEL-24

FDA says additional phase III trial needed for approval of MCNA

Immunogen starts phase I trial of IMGN-779 in AML

IVA-337 demonstrates good safety and tolerability in phase IIa diabetes trial

Start of phase II trial evaluating GSK-3196165 in inflammatory hand osteoarthritis

Pieris licenses intellectual property related to Enumeral's anti-PD-1 antibody program

OSE Pharma and Effimune sign merger treaty to create OSE Immunotherapeutics

RedHill plans confirmatory phase III study for RHB-105

Novel antibacterial agent shows in vitro efficacy

Promathera acquires key assets of cell therapy firm Cytonet

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...